Eosinophils in allergy: Role in disease, degranulation, and cytokines

International Archives of Allergy and Immunology

Volumn 109, Issue 3, 1996, Pages 207-215

  Martin, Laura B ^a   Kita, Hirohito ^a   Leiferman, Kristin M ^a   Gleich, Gerald J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Allergy; Asthma; Atopic dermatitis; Chemokines; Cytokines; Degranulation; Eosinophils; Inflammation

Indexed keywords

CYTOKINE; LIPID; PROTEIN;

ALLERGIC RHINITIS; ALLERGY; ASTHMA; ATOPIC DERMATITIS; CELL SECRETION; DEGRANULATION; EOSINOPHIL; EOSINOPHILIC GASTROENTERITIS; EYE DISEASE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; PATHOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0030050365     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237239     Document Type: Article

References (147)

1. Spry CFJ. Kay AB. Gleich GJ: Eosinophils 1992. Immunol Today 1992;13:384-387.
2. Weller PF; Eosinophils: Structure and functions. Curr Opin Immunol 1994;6:85-90.
3. Walsh RE. Gaginclla TS: The eosinophil in inflammatory bowel disease. Scand J Gastro-cntrol 1991;26:1217-1224.
4. Venge P: The human eosinophil in inflammation. Agents Actions 1990:29:122-126.
5. Butterfield JH. Leiferman KM. Gleich G.I: Eosinophil-associated diseases: in Frank MM, Austen KF, Claman UN. Unanue ER (eds): Samter's Immunologic Diseases. Boston. Little. Brown. 1994. vol 1. pp 501-527.
6. Gleich GJ, Kita H, Adolphson CR: Eosinophils; in Frank MM. Austen KF. Claman UN. Unanue ER (eds): Samter's Immunologic Diseases. Boston. Little, Brown. 1994. vol 1. pp 205-245.
7. Ayars GFI, Altman LC. McManus MM. Agosti JM. Baker C, Luchtel DL. Loegering DA. Gleich GJ: Injurious effect of the eosinophil peroxide-halide system and major basic protein on human nasal epithelium in vitro. Am Rev RespirDis 1989;140:125-131.
8. Lee TH, Austen KF: Arachidonic acid metabolism by the 5-lipoxygenase pathway and the effects of alternative dietary fatty acids. Adv Immunol 1986:39:145-175.
9. Shaw RJ. Walsh GM. Cromwell O. Moqbel R. Spry CJF. Kay AB: Activated human eosinophils generate SRS-A leukotricnes following physiological (IgG-dependent) stimulation. Nature 1985;316:150-152.
10. Sedgwick JB, Calhoun WJ, Gleich GJ, Kita M, Abrams JS, Schwartz LB, Volovitz B, Ben-Yaa-kov M, Busse WW: Immediate and late allergic airway response to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis 1991:144: 1274-1281.
11. Kroegol C. Yukawa T. Dent G. Vengc P. Chung KF. Barnes PJ: Stimulation of degranulation from human eosinophils by platelet-activating factor. J Immunol 1989:142:3518-3526.
12. Barnes PJ. Chung KF, Page CP: Platelet-activating factor as a mediator of allergic disease.J Allergy Clin Immunol 1988:81:919-934.
13. Frigas E. Gleich GJ: The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986:77:527-537.
14. Hamann KJ. Gleich GJ. Gundel RH. White SR: Interactions between respiratory epithelium and eosinophil granule proteins in asthma. The eosinophil hypothesis; in Farmer SG. Uav DWP (eds): The Airway Epithelium: Physiology, Pathophysiology, and Pharmacology. New York. Dekker. 1991, pp 255-300.
15. Leiferman KM. Gleich GJ: Cutaneous eosinophilic diseases: in Fitzpalrick TB. Eisen AZ, Wolff K. Frcedberg IM. Austen KF (eds): Dermatology in General Medicine, ed 4. New York. McGraw-Hill. 1993. vol I. pp 1156-1164.
16. Leiferman KM: Eosinophil granule proteins in cutaneous disease: in Gleich GJ. Kay AB (eds): Eosinophils in Allergy and Inflammation. New York. Dekker, 1994, pp 455-469.
17. Leiferman KM, Gleich GJ: The role of eosinophils in atopic dermatitis: in Leung DYM (ed): The Clinical and Immunologic Aspects of Atopic Dermatitis. Austin. Landes Co. in press.
18. Gleich GJ, Frigas E, Loegering DA, Wassom DL, Steinmuller D: Cytotoxic properties of the eosinophil major basic protein. J Immunol 1979:123:2925-2927.
19. Abu-Ghazaleh RI, Gleich GJ, Prendergast FG: Interaction of eosinophil granule major basic protein with synthetic lipid bilayers: A mechanism for toxicity. J MembrBiol 1992:128:153-164.
20. Young JD-E, Peterson CGB, Venge P, Cohn ZA: Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986:321:613-616.
21. Coyle AJ, Uchida D, Ackerman SJ, Mitzner W, Irvin CG: Role of cationic proteins in the airway. Hyperresponsiveness due to airway inflammation. Am J Respir Crit Care Med 1994: 150:S63-S71.
22. Rohtbach MS, Wheatley CL, Slifman NR, Gleich GJ: Activation of platelets by eosinophil granule proteins. J Exp Med 1990; 172:1271-1274.
23. Moy JN, Gleich GJ, Thomas LL: Noneytoloxic activation of neutrophils by eosinophil granule major basic protein: Effect on superoxide anion generation and lysosomal enzyme release. J Immunol 1990:145:2626-2632.
24. O'Donnell MC, Ackerman SJ, Gleich GJ, Thomas LL: Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med 1983:157:1981-1991.
25. Weiler JM, Gleich GJ: Eosinophil granule major basic protein regulates generation of classical and alternative amplification of pathway C3 convertascs in vitro. J Immunol 1988:140: 1605-1610.
26. Weiler JM, Edens RE, Gleich GJ: Eosinophil granule cationic proteins regulate complement. I. Activity on the alternative pathway. J Immunol 1992:149:643-648.
27. Weiler JM, Edens RE, Bell CS, Gleich GJ: Eosinophil granule cationic proteins regulate the classical pathway of complement. Immunology 1995;84:213-219.
28. Motojima S, Frigas E, Loegering DA, Gleich GJ: Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 1989; 139:801-805.
29. Ayars GH, Altman LC, Gleich GJ, Loegering DA, Baker CB: Eosinophil- and eosinophil granule-mediated pneumocyte injury. J Allergy Clin Immunol 1985;76:595-604.
30. Frigas F, Loegering DA, Gleich GJ: Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest 1980:42:35-43.
31. Azzawi M, Johnston PW, Majumdar S, Kay AB. Jeffery PK: T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Resp D is 1992:145: 1477-1482.
32. Filley WV, Holley KE, Kephart GM, Gleich GJ: Identification by immunofluorescence ofcosin-ophil granule major basic protein in lung tissues of patient with bronchial asthma. Lancet 1982:ii: 11-12.
33. Collins DS, Dupuis R. Gleich GJ, Bartemes KR, Koh YY, Pollice M, Albertine KZH, Fish JE, Peters SP: Immunoglobulin E-mcdiated increase in vascular permeability correlates with eosinophilic inflammation. Am Rev Respir Dis 1993:147:677-683.
34. Carlson M, Hakansson L, Peterson C, Stalenheim G, Venge P: Secretion of granule proteins from eosinophils and neutrophils is increased in asthma. J Allergy Clin Immunol 1991:87:306-312.
35. Carlson M, Hakansson L, Kampe M, Stalenheim D, Peterson C, Venge P: Degranulation of eosinophils from pollen-atopic patients with asthma is increased during pollen season. J Allergy Clin Immunol 1992:89:131-139.
36. Bruijnzecl PLB, Rihs S, Virchow J-C, Warringa RAJ, Moser R, Walker C: Early activation or priming' of eosinophils in asthma. Schweiz Med Wochenschr 1992; 122:298-301.
37. Wardlaw AJ, Dunnelte S, Gleich GJ, Collins JV, Kay AB: Eosinophils and mast cells in bronchoalveolar lavage in mild asthma: Relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988:137:62-69.
38. Jacoby DB, Gleich GJ, Fryer AD: Human eosinophil MBP is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 1993:91:1314-1318.
39. Gundcl RH, Letts LG, Gleich GJ: Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991:87:1470-1473.
40. Coyle AJ, Ackerman SJ, Burch R, Proud D, Irvin CG: Human eosinophil granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bra-dykinin generation. J Clin Invest 1995:95: 1735-1740.
41. Rajka G: Atopic dermatitis. Major Probl Dermatol 1975:3:42-104.
42. Leiferman KM: Eosinophils in atopic dermatitis. J Allergy Clin Immunol 1994:94:1310-1317.
43. Leiferman KM, Ackerman SJ, Sampson HA, Haugen HS, Venencie PY, Gleich GJ: Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: Comparison with onchocerciasis. N Engl J Med 1985:313:282-285.
44. Leiferman KM, Fujisawa T, Gray BH, Gleich GH: Extracellular deposition of eosinophil and neutrophil granule proteins in the IgE-mcdiated cutaneous late phase reactions. Lab Invest 1990:62:579-589.
45. Cheng J, Ott N, Peterson E, George T, Gleich GJ, Leiferman KM: Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration (abstract). J Invest Dermatol 1993:100: 545.
46. Ott NL, Gleich GJ, Peterson EA, Fujisawa T, Sur S, Leiferman KM: Assessment of eosinophil and neutrophil participation in atopic dermatitis: Comparison with the IgE-mediated late phase reaction. J Allergy Clin Immunol 1994; 94:120-128.
47. Wassom DL, Loegering DA, Solley GO, Moore SB, Schooley RT, Fauci AS, Gleich GJ: Elevated scrum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest 1981:67:651-661.
48. Kapp A: The role of eosinophils in the pathogenesis of atopic dermatitis - Eosinophil granule proteins as markers of disease activity. Allergy 1993;48:1-5.
49. Leung DY: The immunologic basis of atopic dermatitis. Clin Rev Allergy 1993:11:447-469.
50. Hanifin JM: Pharmacophysiology of atopic dermatitis. Clin Rev Allergy 1986:4:43-65.
51. Hisamatsu K, Ganbo T, Nakazawa T, Murakami Y, Gleich GJ, Makiyama K, Koyama H: Cytotoxicity of human eosinophil granule major basic protein to human nasal sinus mucosa in vitro. J Allergy Clin Immunol 1990:86:52-63.
52. Lim MC, Taylor RM, Naclerio RM: The histology of allergic rhinitis and its comparison to nasal lavage. Am J Respir C'rit Care Med 1995: 151:136-144.
53. Naclerio RM, Baroody FM, Kagev-Sobotka A, Lichtenstein LM: Basophils and eosinophils in allergic rhinitis. J Allergy Clin Immunol 1994: 94:1303-1309.
54. Bascom R, Pipkom U, Proud D, Dunnette S, Gleich GJ, Lichtenstein LM, Naclerio RM: Major basic protein and eosinophil-derived neurotoxin concentrations in nasal lavage fluid after antigen challenge: Effect of systemic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989;84:338-346.
55. Harlin SL, Ansel DG, Lane SR, Myers J, Kephart GM, Gleich GJ: A clinical and pathologic study of chronic sinusitis: The role of eosinophils. J Allergy Clin Immunol 1988:81:867-875.
56. Talley NJ, Kephart GM, McGovern TW, Carpenter HA, Gleich GJ: Deposition of eosinophil granular major basic protein in eosinophilic gastroenteritis and celiac disease. Gastroenterology 1992:103:137-145.
57. Talley NJ, Shorter RG, Phillips SF, Zinsmeister AR: Eosinophilic gastroenteritis: A clinico-pathological study of patients with disease of the mucosa, muscle layer and subserosal tissue. Gut 1990:31:54-58.
58. Keshavarzian A, Savcrymuttu SH, Tai P-C, Thompson M, Barter S, Spry CJF, Chadwick VS: Activated eosinophils in familial eosinophilic gastroenteritis. Gastroenterology 1985; 88:1042-1049.
59. Colombel JF, Torpier G, Janin A, Klein O, Cortot A, Capron M: Activated eosinophils in adult coeliae disease: Evidence fora local release of major basic protein. Gut 1992:33:1190-1194.
60. Udell IJ, Gleich GJ, Allansmith MR, Ackerman SJ, Abelson MB: Eosinophil granule major basic protein and Charcot-Leyden crystal protein in human tears. Am J Ophthalmol 1981:92: 824-828.
61. Troctne SD, Kephart GM, Allansmith MR, Bourne WM, Gleich GJ: Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol 1989:108:57-63.
62. Trocme SD, Kephart GM, Bourne WM, Maguire LJ, Gleich GJ: Eosinophil granule major basic protein in contact lenses of patients with giant papillary conjunctivitis. CLAO J 1990; 16: 219-222.
63. Trocme SD, Kephart GM, Bourne WM, Buckley RJ, Gleich GJ: Eosinophil granule major basic protein deposition in corneal ulcers associated with vernal keratoconjunctivitis. Am J Ophthalmol 1993:115:640-643.
64. Trocme SD, Gleich GJ, Kephart GM, Zicske JD: Eosinophil granule major basic protein inhibition of corneal epithelial wound healing. Invest Ophthalmol Vis Sei 1994:85:3051-3056.
65. Abu-Ghazaleh RI. Fujisawa T, Mcsteckv J, Kyle RA, Gleich GJ: IgA-induced eosinophil de-granulation. J Immunol 1989;142:2393-2400.
66. Kita H, Weiler DA, Abu-Ghazalch R, Sanderson CJ, Gleich GJ: Release of granule proteins from eosinophils cultured with 11-5. J Immunol 1992:149:629-635.
67. Fujisawa T, Abu-Ghazaleh R, Kita H, Sanderson CJ, Gleich GJ: Regulatory effect of cytokines on eosinophil dcgranulation. J Immunol 1990:144:642-646.
68. Kita H. Kalo M, Gleich GJ, Abrams RT: Tyrosine phosphorylation and inositol phosphate productions: Arc early events in human eosinophil activation stimulated by immobilized secretory IgA and IgG? J Allergy Clin Immunol 1994;94:1272-2181.
69. Dunne DW, Richardson BA, Jones FM, Clark M, Thorne KJ, Butterworth AE: The use of mouse/human chimaeric antibodies to investigate the roles of different antibody isotypes, including lgA2, in the killing of Schistosoma mansoni schistosomula by eosinophils. Parasite Immunol 1993:15:181-185.
70. Gounni AS, Lamkhioued B, Ochiai K, Tanaka Y, Delaporte E, Capron A, Kinet J-P. Capron M: High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994:367:183-186.
71. Tomassini M, Tsicopoulos A, Tai P-C, Gruart V, Tonnel AB, Prin L, Capron A, Capron M: Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation. J Allergy Clin Immunol 1991;88:365-375.
72. Khaliffe J, Capron M, Cesbron JY, Tai P-C, Taelman H, Prin L, Capron A: Role of specific IgE antibodies in peroxidase (EPO) release from human eosinophils. J Immunol 1986; 137-1659-1664.
73. Gounm AS, Lamkhioued B, Delaporte E, Dubost A, Kinet J-P, Capron A, Capron M: The high-affmity IgE receptor on eosinophils: From allergy to parasites or from parasites to allergy? J Allergy Clin Immunol 1994;94:1214-1216.
74. Kaneko M, Swanson VI, Gleich GJ, Kita H: Allergen-specific IgCI and IgG3 through FcγII induce eosinophil degranulation. J Clin Invest 1995:95:2813-2821.
75. Horie S, Kita H: CD I lb/CD 18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocytc-macrophage colony-stimulating factor and platelet-activating factor. J Immunol 1994:152: 5457-5467.
76. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA: RANTES and macrophage inflammatory protein let induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992:176:1489-1495.
77. Kita H, Abu-Ghazaleh RI, Sur S, Gleich GJ: Eosinophil major basic protein induces dcgran-ulation and IL-8 production by human eosinophils. J Immunol 1995;154:4749-4758.
78. Winqvist I, Olofsson T, Olsson I: Mechanisms for eosinophil degranulation: Release of eosinophil cationic protein. Immunology 1984:51:1-8.
79. Kemen P. Wymann MP. Von Tscharner V. De-ranleau DA. Tai P-C. Spry CJ. Dahinden CA. Baggiolini M: Shape changes, exocytosis. and cytosolic free calcium changes in stimulated human eosinophils. J Clin Invest 1991:87: 2012-2017.
80. Daffem PJ, Pfeifer PH, Ember JA, Hugli TE: C3a is a chemotaxin for human eosinophils but not for neutrophils. 1. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med 1995:181:2119-2127.
81. Kroegel C, Gietrtbyez MA, Barnes PJ: Characterization of eosinophil activation by peptides: Differential effects of substance P. melittin. and FMet-Leu-Phe. J Immunol 1990:145:2581-2587.
82. Ishikawa T, Wicher K, Arbesman CE: In vitro and in vivo studies on uptake of antigen-anti-body complexes by eosinophils, Int Arch Allergy AppI Immunol 1974:46:230-248.
83. Butterworth AE, Vadas MA, Wassom DL, Dessein A, Hogan M, Sherry B, Gleich GJ, David JR: Interactions between human eosinophils and schistosomula of Schixtastinw mansoni. II. The mechanism of irreversible eosinophil adherence. J Exp Med 1979;150:1456-1471.
84. Capron M, Kazatchkine VID, Fischer E, Joseph M, Butterworth AE, Kusnierz J-P, Prin L, Papin J-P. Capron A: Functional role of the α-chain of complement receptor type 3 in human eosinophil-dependent antibody-mediated cytotoxicity against schistosomes. J Immunol 1987:139: 2059-2065.
85. 2 integrin in the activation of eosinophils stimulated with IgC. J Immunol 1995:155:2631-2641.
86. Wegner CD: Adhesion glycoproteins as regulators of airway inflammation: Emphasis on the role of ICAM-1; in Holgate ST. Austen KF, Lichtenstein LM, Kay AB (eds): Asthma: Physiology. Pharmacology and Treatment. London. Academic Press. 1993. pp 227-242.
87. Bittleman DB, Casale TB: Allergic models and cytokines. Am J Respir Crit Care Med 1994: 180:S72-S76.
88. Durham SR: Allergic inflammation (review). Pediatr Allergy Immunol 1993:4(suppl4):7-12.
89. Walker C, Virchow JC, Bruijnzecl PLB, Blaser K: T cell subsets and their soluble products regulate cosinophilia in allergic and notiallergic asthma. J Immunol 1991:46:1829-1835.
90. Walker C, Kagi MK, Ingold P, Braun P, Blaser K, Bruijnzeel-Kootnen CA, Wuthrich B: Atopic dermatitis: Correlation of peripheral blood T cell activation, cosinophilia and serum factors with clinical severity. Clin Exp Allergy 1993; 23:145-153.
91. Walker C, Bauer W, Braun RK, Menz G, Braun P, Schwarz F, Hansel TP, Villiger B: Activated T cells and cytokines in bronchoalvcolar lavages from patients with various lung diseases associated with cosinophilia. Am J Respir Crit Care Med 1994:150:1038-1048.
92. Simon HU, Grotzer M, Nikolaizik WH, Blaser K, Schoni MH: High altitude climate therapy reduces peripheral blood T lymphocyte activation. cosinophilia. and bronchial obstruction in children with housc-dust mite allergic asthma. Pediatr Pulmonol 1994:17:304-311.
93. Moqbel R, Levi-Schaffer F, Kay AB: Cytokine generation by eosinophils (review). J Allergy Clin Immunol 1994:94:1183-1188.
94. Kita H, Olmishi T, Okubo Y, Weiler D, Abrams JS, Gleicli GJ: Granulocyte/macrophage colony-stimulating factor and interleukin-3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991:174:745-748.
95. Moqbel R, Hamid Q, Ying S, Barkans J, Hartnell A, Tsicopoulos A, Wardlaw AJ, Kay AB: Expression of mRNA and immunoreactivity for the granulocyte macrophage colony-stimulating factor in activated human eosinophils. J Exp Med 1991:174:749-752.
96. Dubucquoi S, Desreumaux P, Janin A, Klein O, Goldman M, Tavernier J, Capron A, Capron M: lnterleukin-5 synthesis by eosinophils: Association with granules and immunoglobulin-dependent secretion. J Exp Med 1994:179:703-708.
97. Stem M, Meagher L, Savill J, Haslett C: Apoptosis in human eosinophils: Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992:148:3543-3549.
98. Simon HU, Blaser K: Inhibition of programmed eosinophil death: A key pathogenic event for cosinophilia? Immunol Today 1995;16:53-55.
99. Yamaguchi YY, Suda T, Olua S, Tominaga K, Miura Y, Kasahara T: Analysis of the survival of mature human eosinophils: lnterleukin-5 prevents apoptosis in mature human eosinophils. Blood 1991;78:2542-2547.
100. Her E, Frazer J, Austen KF, Owen WF Jr: Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J Clin Invest 1991:88:1982-1987.
101. Melani C, Mattia GF, Silvani A, Care A, Rivoltini L, Parmiani G, Colombo MD: lnterleu-kin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes. Blood 1993:81:2744-2749.
102. Hamid Q, Barkans J, Meng Q, Ying S, Abrams JS, Kay AB, Moqbel R: Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 1992:80:1496-1501.
103. Weller PF, Rand TH, Barrett T, Elovic A, Wong DTW, Einberg RW: Accessory cell function of human eosinophils: HLA-DR-dependent, MHC-restricted antigen presentation and IL-1 a formation. J Immunol 1993;150:2554-2562.
104. Dell’ozo V, De Andres B, Martin E, Maruri N, Zubcldia JM, Palomino P, Lahoz C: Murine eosinophils and IL-I: αIL-I mRNA detection by in situ hybridization. Production and release of IL-I from peritoneal eosinophils. J Immunol 1990;144:3117-3122.
105. Lamkhioued B, Aldebert D, Gounni AS, Delaporte E, Goldman M, Capron A, Capron M: Synthesis of cytokines by eosinophils and their regulation. Int Arch Allergy Immunol 1995; 107:122-123.
106. Nonaka M, Nonaka R, Wooley K, Adelroth E, Miura K, Okhawara Y, Glibetic M, Nakano K, O'Byrne P, Dolovich J, Jordana M: Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues - IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995; 155:3234-3244.
107. Lim KG, Wan HC, Resnick M, Wong DTW, Cruikshank WW, Kornfeld H, Center DM, Weller PF: Human eosinophils release the lymphocyte and eosinophil active cytokines, RANTES and lymphocyte chemoattractant factor. Int Arch Allergy Immunol 1995:107: 342.
108. Costa JJ, Matossian K, Resnick MB, Beil WJ, Wong DT, Gordon JR, Dvorak AM, Weller PF, Galli SJ: Human eosinophils can express the cytokines tumor necrosis factor-α and macrophage inflammatory protein-1α. J Clin Invest 1993:91:2673-2684.
109. Lukács NW, Stricter RM, Shaklec CL, Chensue SW, Kunkel SI.: Macrophage inflammatory protein-1α influences eosinophil recruitment in antigen-specific airway inflammation. Eur J Immunol 1995:25:245-251.
110. Simon HU, Yousefi S, Weber M, Simon D, Holzer C, Hartung K, Blaser K: Human peripheral blood eosinophils express and release interleukin-8. Int Arch Allergy Immunol 1995: 107:124-126.
111. Yousefi S, Hemmann S, Weber M, Holzer C, Hartung K, Blaser K, Simon HU: IL-8 is expressed by human peripheral blood eosinophils: Evidence for increased secretion in asthma. J Immunol 1995:154:5481-5490.
112. Braun RK, Franchini M, Erard R, Rihs S, DeVries UM, Blaser K, Hansel TT, Walker C: Human peripheral blood eosinophils produce and release intcrleukin-8 on stimulation with calcium ionophore. Fur J Immunol 1993:23: 956-960.
113. Tanaka Y, Delaporte E, Dubucquoi S, Gounni AS, Porehet E, Capron A, Capron VI: Intcrlcu-kin-5 messenger RNA and immunoreactivc protein expression by activated eosinophils in lesional atopic dermatitis skin. J Invest Dermatol 1994;103:589-592.
114. Desreumaux P, Janin A, Colombel JF, Prin L, Plumas J, Emilie D, Torpier G, Capron A, Capron M: lnterleukin-5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with cocliac disease. J Exp Med 1992:175:293-296.
115. Dubucquoi S, Janin A, Desreumaux P, Rigot JM, Copin MC. François M, Torpier G, Capron M, Gosselin B: Evidence for eosinophil activation in eosinophilic cystitis. Eur Urol 1994:25: 254-258.
116. Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, Howarth PH: Immu-nolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast eel I as a source of IL-4.1L-5 and 11.-6 in human allergic mucosal inflammation. J Immunol 1993:151:3853-3865.
117. Bradding P, Roberts JA, Britten KM, Monte-fort S, Djukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST: Interleukin-4. -5. -6 and tumor necrosis factor-u in normal and asthmatic airways: Evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994:10:471-480.
118. Broide DH, Paine MM, Firestein CIS: Eosinophils express interlcukin-5 and granulocyte-macrophage colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992:90:1414-1424.
119. Ohno I, Lea R, Finotto S, Marshall J, Denburg J, Dolovich J, Gauldic J, Jordana VI: Granulocyte macrophage colony-stimulating factor gene expression by eosinophils in nasal polyposis. Am J Respir Cell Mol Biol 1991:5:505-510.
120. Elovic A, Wong DT, Weller PF, Matossian K, Galli SJ: Expression of transforming growth factors-α and β, messenger RNA and products by eosinophils in nasal polyps. J Allergy Clin Immunol 1994:93:864-869.
121. Biel WJ, Weller PF, Tzizik DM, Galli SJ, Dvorak AM: Ultrastructural immunogold localization of tumor necrosis factor-α to the matrix compartment of eosinophil secondary granules in patients with idiopathic hypercosino-philic syndrome. J Histochem Cytochem 1993;41:1611-1615.
122. Finotto S, Ohno I, Marshall JS, Gauldic J, Denberg JA, Dolovich J, Clark DA, Jordana M: TNF-α production by eosinophils in upper airways inflammation (nasal polyposis). J Immunol 1994:153:2278-2289.
123. Tan X, Hsuch W, Gonzalez-Crussi F: Cellular localization of tumor necrosis factor (TNF)-u transcripts in normal bowel and in necrotizing enterocolitis: TNF gene expression by Paneth cells, intestinal eosinophils and macrophages. Am J Pathol 1993; 142:1858-1865.
124. Oppenheim JJ, Zachariac CO, Mukaida N, Matsushima K: Properties of the novel proin-fiammatory supergene 'intercrine' cytokine family (review). Annu Rev Immunol 1991:9: 617-648.
125. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B, Moser B, Baggiolini M, Sykes BD: Structure-activity relationships ofchemo-kines. J Leukoc Biol 1995:57:703-711.
126. Baggiolini M, Dewald B, Moser B: lntcrleu-kin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994:55: 97-179.
127. Schall TJ, Bacon KB: Chemokines. leukocyte trafficking and inflammation (review). Curr Opin Immunol 1994:6:865-873.
128. Schall TJ: Biology of the RANTES/S1S cytokine family (review). Cytokine 1991:3:165-183.
129. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992;176:587-592.
130. Dahinden CA, Geiser T, Brunner T, von Tschamer V, Caput D, Ferrara P, Minty A, Baggiolini M: Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating cytokine. J Exp Med 1994; 179:751-756.
131. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, Truong O, Hsuan JJ, Williams TJ: Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 1994:179:881-887.
132. Noso N, Proost P, Van Damme J, Schroder JM: Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophils and desensitize the chemotactic responses towards RANTES. Biochem Biophys Res Commun 1994:200:1470-1476.
133. Ebisawa M, Yamada T, Bickel C, Klunk D, Schleimer RP: Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokinc RANTES. J Immunol 1994:153: 2153-2160.
134. Schweizer RC, Weimers BAC, Raaijmakers JAM, Zanen P, Lammers JWJ, Koenderman L: RANTES- and interlcukin-8-induced responses in normal human eosinophils: Effects of priming with interleukin-5. Blood 1994:83: 3697-3704.
135. Alam R, Stafford S, Forsythe P, Harrison R, Faubion D, Lett-Brown MA, Grant JA: RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993: 150:3442-3448.
136. Weber M, Dahinden CA: Basophil and eosinophil activation by CC chemokines. Int Arch Allergy Immunol 1995:107:148-150.
137. Meurer R, Van Riper G, Feeney W, Cunningham P, Hora D, Springer MS, MacIntyre DE, Rosen H: Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not monocyte chemoattractant protein 1. human macrophage inflammatory protein lu, or human interleukin-8. J Exp Med 1993; 178:1913-1921.
138. Baggiolini M, Dahinden CA: CC chemokines in allergic inflammation. Immunol Today 1994.15:127-133.
139. Jose PJ, Adcock IM, Griffiths-Johnson DA, Berkman N, Wells TNC, Williams TJ. Power CA: Eotaxin: Cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs. Biochem Biophys Res Commun 1994: 205:788-794.
140. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ: The chemokinc. eotaxin. activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 1993:197: 1167-1172.
141. Rothenberg ME, Luster AD, Leder P: Murine eotaxin: An eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induccd tumor suppression. Proc Natl Acad Sei USA 1995;92:8960-8964.
142. Schmi R, Cromwell O, Wardlaw AJ, Moqbel R, Kay AB: lntcrlcukin-8 is a chemoattractant for eosinophils purified from subjects with a blood eosinophilia but not from normal healthy subjects. Clin Exp Allergy 1993:23: 1027-1036.
143. Warringa RAJ, Koenderman L, Kok PTM, Krcukniet J, Bruijnzcel PLB: Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3? Blood 1991;77:2694-2700.
144. Warringa RAJ, Schweizer RC, Maikoe T, Kuijper PHM, Bruijnzcel PBL, Koenderman L: Modulation of eosinophil chemotaxisby interleukin-5. Am.I Respir Cell Mol Biol 1992;7: 631-636.
145. Douglass JA, Gurr C, Shute JK, Church MK, Holgate ST: The effect of intranasal challenge with interleukin-8. Adv Exp Med Biol 1994; 351:220-221.
146. Bachen C, Wagenmann M, Hauser U: Proin-flammatory cytokines: Measurement in nasal secretion and induction of adhesion receptor expression. Int Arch Allergy Immunol 1995; 107:106-108.
147. Bachen C, Hauser U, Prent B, Rudack C, Ganzer U: Proinflammatory cytokines in allergic rhinitis. Eur Arch Otorhinolaryngol 1995; 252(suppl):S44-S49.